Goldman Sachs has initiated coverage on Suven Pharmaceuticals with a ‘Buy’ rating and a target price of ₹1,350, expecting a sharp recovery and structural growth beginning FY26.
The brokerage expects growth to be driven by four major catalysts:
-
Continued momentum in key drugs such as Empagliflozin, Finerenone, and Antibody Drug Conjugates (ADCs);
-
New drug/indication approvals like Zongertinib and Nerandomilast;
-
Successful integration of acquired entities Cohance, Sapala, and NJ Bio;
-
A macro recovery in the agrochemicals space.
With these drivers, Goldman anticipates the combined entity to deliver EBITDA growth of over 20% CAGR organically over the medium term, placing Suven Pharma among top growth picks in its coverage.
Disclaimer: The above views are of the broker’s and not the author or the publication’s. Please make any and every investment decision after consulting your financial advisor.
